Vamsee D. Myneni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vamsee D. Myneni has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Eva Mezey
Adult Stem Cell Section, National Institutes of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
3 shared publications - Ildikó Szalayova
Adult Stem Cell Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD
3 shared publications - Lynn Vitale-Cross
Adult Stem Cell Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD
3 shared publications - Balázs Mayer
Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, 1085 Budapest, Hungary
2 shared publications - Constance Tom Noguchi
Molecular Medicine Branch National Institute of Diabetes and Digestive and Kidney Diseases NIH Bethesda MD USA
2 shared publications Heather Rogers
Molecular Medicine Branch National Institute of Diabetes and Digestive and Kidney Diseases NIH Bethesda MD USA
2 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2408-2416
Osteocyte-derived erythroferrone regulates liver hepcidin during stress erythropoiesis
Our knowledge of which bone marrow (BM) cells affect red cell production is still incomplete. To explore the role of osteocytes in the process, we performed bulk RNA sequencing of osteocytes isolated from control and phlebotomized mice. The second top upregulated gene after phlebotomy was erythroferrone (Erfe). Erfe expression in osteocytes was also upregulated after erythropoietin (EPO) treatment and hypoxia in vitro. To explore whether osteocytes contribute to systemic ERFE levels, we generated 2 mouse models. We first transplanted wild-type BM in Erfe−/− mice, creating a model where ERFE is produced in the BM but not by osteocytes. After phlebotomy, liver hepcidin suppression was significantly lower in mice where the osteocytes could not produce ERFE. To confirm that osteocytes are responsible for this difference, we generated mice lacking EPO receptors in osteocytes by crossing Eporflox/flox and Dmp1-Cre mice. After phlebotomy, these mice demonstrated reduced hepcidin suppression in the liver and higher circulating serum hepcidin levels compared with controls. Our work identified a novel function of osteocytes in suppressing systemic hepcidin levels during stress erythropoiesis.
- 1 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2408-2416
Open AccessOsteocyte-derived erythroferrone regulates liver hepcidin during stress erythropoiesis
Our knowledge of which bone marrow (BM) cells affect red cell production is still incomplete. To explore the role of osteocytes in the process, we performed bulk RNA sequencing of osteocytes isolated from control and phlebotomized mice. The second top upregulated gene after phlebotomy was erythroferrone (Erfe). Erfe expression in osteocytes was also upregulated after erythropoietin (EPO) treatment and hypoxia in vitro. To explore whether osteocytes contribute to systemic ERFE levels, we generated 2 mouse models. We first transplanted wild-type BM in Erfe−/− mice, creating a model where ERFE is produced in the BM but not by osteocytes. After phlebotomy, liver hepcidin suppression was significantly lower in mice where the osteocytes could not produce ERFE. To confirm that osteocytes are responsible for this difference, we generated mice lacking EPO receptors in osteocytes by crossing Eporflox/flox and Dmp1-Cre mice. After phlebotomy, these mice demonstrated reduced hepcidin suppression in the liver and higher circulating serum hepcidin levels compared with controls. Our work identified a novel function of osteocytes in suppressing systemic hepcidin levels during stress erythropoiesis.
- 14 December 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 94 (5) , 888-890
Commentary on Winzeler et al ‘Low arginine vasopressin levels in patients with diabetes insipidus are not associated with anaemia’
- 14 December 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 94 (5) , 888-890
Commentary on Winzeler et al ‘Low arginine vasopressin levels in patients with diabetes insipidus are not associated with anaemia’
- 29 November 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (418)
Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia
Vasopressin stimulates erythropoiesis.
- 29 November 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (418)
Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia
Vasopressin stimulates erythropoiesis.